Effects of orexin 2 receptor activation on apnea in the C57BL/6J mouse

Respiratory Physiology and Neurobiology

Volumn 200, Issue , 2014, Pages 118-125

  Moore, Michael W ^a,d   Akladious, Afaf ^a,d   Hu, Yufen ^a,b,d   Azzam, Sausan ^a,c,d   Feng, Pingfu ^a,b,d   Strohl, Kingman P ^a,c,d  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b Neogene Biosciences LLC   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Mouse model; Orexin 2 agonist; Orexin 2 antagonist; Receptors; Sleep apnea; Sleep disordered breathing

Indexed keywords

OREXIN 2 RECEPTOR; OREXIN B; TCS OX 2 29; UNCLASSIFIED DRUG; 1-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLINYL)-3,3-DIMETHYL-2-((4-PYRIDINYLMETHYL)AMINO)-1-BUTANONE; CD200R1 PROTEIN, MOUSE; CENTRAL NERVOUS SYSTEM AGENTS; ISOQUINOLINE DERIVATIVE; OREXIN RECEPTOR; OREXIN RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APNEA; ARTICLE; BLOOD BRAIN BARRIER; BODY PLETHYSMOGRAPHY; BREATHING RATE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; FEMALE; MALE; MOUSE; NONHUMAN; NONREM SLEEP; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REM SLEEP; SLEEP WAKING CYCLE; WAKEFULNESS; AGONISTS; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ELECTRODE IMPLANT; ELECTROENCEPHALOGRAPHY; INDWELLING CATHETER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PLETHYSMOGRAPHY; POLYSOMNOGRAPHY; RANDOMIZATION; SEXUAL DEVELOPMENT; SLEEP;

ANIMALS; APNEA; BRAIN; CATHETERS, INDWELLING; CENTRAL NERVOUS SYSTEM AGENTS; DISEASE MODELS, ANIMAL; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; FEMALE; ISOQUINOLINES; MALE; MICE, INBRED C57BL; OREXIN RECEPTOR ANTAGONISTS; OREXIN RECEPTORS; PLETHYSMOGRAPHY; POLYSOMNOGRAPHY; PYRIDINES; RANDOM ALLOCATION; SEX CHARACTERISTICS; SLEEP; WAKEFULNESS;

EID: 84904124185     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.03.014     Document Type: Article

References (43)

1. Anaclet C., Parmentier R., Ouk K., Guidon G., Buda C., Sastre J.P., Akaoka H., Sergeeva O.A., Yanagisawa M., Ohtsu H., Franco P., Haas H.L., Lin J.S. Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J. Neurosci. 2009, 29:14423-14438.
2. Carley D.W., Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am. J. Respir. Crit. Care Med. 1999, 160:1824-1829.
3. Carley D.W., Onal E., Aronson R., Lopata M. Breath-by-breath interactions between inspiratory and expiratory duration in occlusive sleep apnea. J. Appl. Physiol. 1989, 66:2312-2319.
4. Carley D.W., Trbovic S.M., Radulovacki M. Hydralazine reduces elevated sleep apnea index in spontaneously hypertensive (SHR) rats to equivalence with normotensive Wistar-Kyoto rats. Sleep 1996, 19:363-366.
5. Carley D.W., Berecek K., Videnovic A., Radulovacki M. Sleep-disordered respiration in phenotypically normotensive, genetically hypertensive rats. Am. J. Respir. Crit. Care Med. 2000, 162:1474-1479.
6. Chen L., Brown R.E., McKenna J.T., McCarley R.W. Animal models of narcolepsy. CNS Neurol. Disord. Drug Targets 2009, 8:296-308.
7. Conduit R., Sasse A., Hodgson W., Trinder J., Veasey S., Tucker A. A neurotoxinological approach to the treatment of obstructive sleep apnoea. Sleep Med. Rev. 2007, 11:361-375.
8. Corcoran A., Richerson G., Harris M. Modulation of respiratory activity by hypocretin-1 (orexin A) in situ and in vitro. Adv. Exp. Med. Biol. 2010, 669:109-113.
9. Davis E.M., O'Donnell C.P. Rodent models of sleep apnea. Respir. Physiol. Neurobiol. 2013, 188:355-361.
10. Davis E.M., Locke L.W., McDowell A.L., Strollo P.J., O'Donnell C.P. Obesity accentuates circadian variability in breathing during sleep in mice but does not predispose to apnea. J. Appl. Physiol. (1985) 2013, 115:474-482.
11. Dempsey J.A., Veasey S.C., Morgan B.J., O'Donnell C.P. Pathophysiology of sleep apnea. Physiol. Rev. 2010, 90:47-112.
12. Dias M.B., Li A., Nattie E.E. Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J. Physiol. 2009, 587:2059-2067.
13. Diniz Behn C.G., Klerman E.B., Mochizuki T., Lin S.C., Scammell T.E. Abnormal sleep/wake dynamics in orexin knockout mice. Sleep 2010, 33:297-306.
14. Dutschmann M., Kron M., Morschel M., Gestreau C. Activation of Orexin B receptors in the pontine Kolliker-Fuse nucleus modulates pre-inspiratory hypoglossal motor activity in rat. Respir. Physiol. Neurobiol. 2007, 159:232-235.
15. Feng P., Vurbic D., Wu Z., Strohl K.P. Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res. 2007, 1154:163-172.
16. Feng P., Vurbic D., Wu Z., Hu Y., Strohl K.P. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J. Psychopharmacol. 2008, 22:784-791.
17. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
18. Friedman L., Haines A., Klann K., Gallaugher L., Salibra L., Han F., Strohl K.P. Ventilatory behavior during sleep among A/J and C57BL/6J mouse strains. J. Appl. Physiol. 2004, 97:1787-1795.
19. Fung S.J., Yamuy J., Sampogna S., Morales F.R., Chase M.H. Hypocretin (orexin) input to trigeminal and hypoglossal motoneurons in the cat: a double-labeling immunohistochemical study. Brain Res. 2001, 903:257-262.
20. Gestreau C., Bevengut M., Dutschmann M. The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. Curr. Opin. Pulm. Med. 2008, 14:512-518.
21. Han F., Subramanian S., Dick T.E., Dreshaj I.A., Strohl K.P. Ventilatory behavior after hypoxia in C57BL/6J and A/J mice. J. Appl. Physiol. 2001, 91:1962-1970.
22. Han F., Mignot E., Wei Y.C., Dong S.X., Li J., Lin L., An P., Wang L.H., Wang J.S., He M.Z., Gao H.Y., Li M., Gao Z.C., Strohl K.P. Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur. Respir. J. 2010, 36:577-583.
23. Haxhiu M.A., Mack S.O., Wilson C.G., Feng P., Strohl K.P. Sleep networks and the anatomic and physiologic connections with respiratory control. Front. Biosci. 2003, 8:D946-D962.
24. Kuwaki T. Orexinergic modulation of breathing across vigilance states. Respir. Physiol. Neurobiol. 2008, 164:204-212.
25. Kuwaki T. Hypothalamic modulation of breathing. Adv. Exp. Med. Biol. 2010, 669:243-247.
26. Li A., Nattie E. Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J. Physiol. 2010, 588:2935-2944.
27. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4649-4654.
28. Moore M.W., Chai S., Gillombardo C.B., Carlo A., Donovan L.M., Netzer N., Strohl K.P. Two weeks of buspirone protects against posthypoxic ventilatory pauses in the C57BL/6J mouse strain. Respir. Physiol. Neurobiol. 2012, 183:35-40.
29. Nattie E., Li A. Respiration and autonomic regulation and orexin. Prog. Brain Res. 2012, 198:25-46.
30. O'Donnell C.P., Tankersley C.G., Polotsky V.P., Schwartz A.R., Smith P.L. Leptin, obesity, and respiratory function. Respir. Physiol. 2000, 119:163-170.
31. Onal E., Burrows D.L., Hart R.H., Lopata M. Induction of periodic breathing during sleep causes upper airway obstruction in humans. J. Appl. Physiol. 1986, 61:1438-1443.
32. Peever J.H., Lai Y.Y., Siegel J.M. Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J. Neurophysiol. 2003, 89:2591-2600.
33. Scammell T.E., Willie J.T., Guilleminault C., Siegel J.M. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009, 32:111-116.
34. Shahid I.Z., Rahman A.A., Pilowsky P.M. Orexin and central regulation of cardiorespiratory system. Vitam. Horm. 2012, 89:159-184.
35. Shirasaka T., Takasaki M., Kannan H. Cardiovascular effects of leptin and orexins. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284:R639-R651.
36. Veasey S. Treatment of obstructive sleep apnoea. Indian J. Med. Res. 2010, 131:236-244.
37. Wellman A., Eckert D.J., Jordan A.S., Edwards B.A., Passaglia C.L., Jackson A.C., Gautam S., Owens R.L., Malhotra A., White D.P. A method for measuring and modeling the physiological traits causing obstructive sleep apnea. J. Appl. Physiol. 2011, 110:1627-1637.
38. Yamauchi M., Dostal J., Strohl K.P. Acetazolamide protects against posthypoxic unstable breathing in the C57BL/6J mouse. J. Appl. Physiol. 2007, 103:1263-1268.
39. Yamauchi M., Dostal J., Kimura H., Strohl K.P. Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains. J. Appl. Physiol. 2008, 105:518-526.
40. Yamauchi M., Ocak H., Dostal J., Jacono F.J., Loparo K.A., Strohl K.P. Post-sigh breathing behavior and spontaneous pauses in the C57BL/6J (B6) mouse. Respir. Physiol. Neurobiol. 2008, 162:117-125.
41. Yamauchi M., Kimura H., Strohl K.P. Mouse models of apnea: strain differences in apnea expression and its pharmacologic and genetic modification. Adv. Exp. Med. Biol. 2010, 669:303-307.
42. Yamauchi M., Tamaki S., Yoshikawa M., Ohnishi Y., Nakano H., Jacono F.J., Loparo K.A., Strohl K.P., Kimura H. Differences in breathing patterning during wakefulness in patients with mixed apnea-dominant vs obstructive-dominant sleep apnea. Chest 2011, 140:54-61.
43. Young J.K., Wu M., Manaye K.F., Kc P., Allard J.S., Mack S.O., Haxhiu M.A. Orexin stimulates breathing via medullary and spinal pathways. J. Appl. Physiol. 2005, 98:1387-1395.